Are pregnancies with lupus but without APS of good prognosis?


Journal

Autoimmunity reviews
ISSN: 1873-0183
Titre abrégé: Autoimmun Rev
Pays: Netherlands
ID NLM: 101128967

Informations de publication

Date de publication:
Apr 2020
Historique:
received: 10 10 2019
accepted: 13 10 2019
pubmed: 1 3 2020
medline: 4 4 2020
entrez: 1 3 2020
Statut: ppublish

Résumé

Pregnancies in women with systemic lupus erythematosus (SLE) are at risk of unfavorable perinatal outcomes, especially when antiphospholipid antibody syndrome (APS) is present. Their prognosis is less clear in other situations. To assess pregnancy prognosis in women with SLE but not APS compared with a control series and determine the poor prognostic factors, if any, detectable before 15 weeks' gestation. This retrospective case-control study included 137 women with SLE, including 114 without APS, and 274 control women. Unfavorable perinatal outcome was defined by perinatal death (≥ 22 weeks of gestation) or preterm delivery ≤35 weeks. Pregnancies of the 114 women with SLE but not APS were at more than twice the risk of unfavorable perinatal outcomes compared with those in the control group (18/114 (15.8%) vs 21/274 (7.7%), OR 2.3, 95% 1.1-4.7). After logistic regression, three factors detectable before 15 weeks were associated with an unfavorable perinatal outcome: i. proteinuria and/or hypertension (in 19.3% of the pregnancies) ii. lack of cutaneous lupus (26.3%), and iii. a history of thrombocytopenia-leukopenia-anemia (19.3%). When these factors were absent, the risk of a poor perinatal outcome was very low (3.3%) but increased strongly for pregnancies with one (22.2%) or at least two (44.4%) of these factors. Among women with SLE but not APS in the first trimester, only the presence of risk factors increases the likelihood of an unfavorable perinatal outcome. Pregnancies with SLE but not APS are at risk of unfavorable perinatal outcomes only if risk factors are present.

Sections du résumé

BACKGROUND BACKGROUND
Pregnancies in women with systemic lupus erythematosus (SLE) are at risk of unfavorable perinatal outcomes, especially when antiphospholipid antibody syndrome (APS) is present. Their prognosis is less clear in other situations.
OBJECTIVES OBJECTIVE
To assess pregnancy prognosis in women with SLE but not APS compared with a control series and determine the poor prognostic factors, if any, detectable before 15 weeks' gestation.
MATERIAL AND METHODS METHODS
This retrospective case-control study included 137 women with SLE, including 114 without APS, and 274 control women. Unfavorable perinatal outcome was defined by perinatal death (≥ 22 weeks of gestation) or preterm delivery ≤35 weeks.
RESULTS RESULTS
Pregnancies of the 114 women with SLE but not APS were at more than twice the risk of unfavorable perinatal outcomes compared with those in the control group (18/114 (15.8%) vs 21/274 (7.7%), OR 2.3, 95% 1.1-4.7). After logistic regression, three factors detectable before 15 weeks were associated with an unfavorable perinatal outcome: i. proteinuria and/or hypertension (in 19.3% of the pregnancies) ii. lack of cutaneous lupus (26.3%), and iii. a history of thrombocytopenia-leukopenia-anemia (19.3%). When these factors were absent, the risk of a poor perinatal outcome was very low (3.3%) but increased strongly for pregnancies with one (22.2%) or at least two (44.4%) of these factors.
CONCLUSION CONCLUSIONS
Among women with SLE but not APS in the first trimester, only the presence of risk factors increases the likelihood of an unfavorable perinatal outcome.
PRECIS CONCLUSIONS
Pregnancies with SLE but not APS are at risk of unfavorable perinatal outcomes only if risk factors are present.

Identifiants

pubmed: 32112993
pii: S1568-9972(20)30037-9
doi: 10.1016/j.autrev.2020.102489
pii:
doi:

Types de publication

Letter

Langues

eng

Sous-ensembles de citation

IM

Pagination

102489

Informations de copyright

Copyright © 2020 Elsevier B.V. All rights reserved.

Auteurs

Aurore Marx-Deseure (A)

Hopital d'Arras, Pôle Mère Enfant, F-62000 Arras, France. Electronic address: aurore.marx@ch-arras.fr.

Julien Labreuche (J)

Univ. Lille, EA 2694: Epidémiologie et qualité des soins, F-59000 Lille, France.

David Launay (D)

Univ Lille, CHU Lille, CHU Lille, Service de Médecine Interne, F-59000 Lille, France; Univ Lille, INSERM U995, LIRIC, Lille Inflammation Research International Center, F-59000 Lille, France.

Sandrine Depret (S)

Univ Lille, CHU Lille, Pôle Femme Mère Nouveau-né, F-59000 Lille, France.

Damien Subtil (D)

Univ. Lille, EA 2694: Epidémiologie et qualité des soins, F-59000 Lille, France; Univ Lille, CHU Lille, Pôle Femme Mère Nouveau-né, F-59000 Lille, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH